Skip to main content
. 2019 Jun 24;116(28):14154–14163. doi: 10.1073/pnas.1813580116

Fig. 6.

Fig. 6.

K201 mitigates podocyte ER stress-mediated proteinuric kidney disease progression. (A) K201 inhibits urinary calpain activity in Tg-C321R mice after 2 wk of injection. Urinary calpain activity/Cr was measured by luciferase assay from both K201- and 20% HBC-treated Tg-C321R mice at pretreatment (P17–P19) and at weekly intervals posttreatment. The urinary calpain activity/Cr in the 20% HBC-treated Tg-C321R mice at the respective time points was set as 1 (n = 6 per group). *P < 0.05, ***P < 0.001 by t test. (B) K201 (12.5–15 mg/kg, once daily, 5 d per week) by intraperitoneal injection attenuates albuminuria in Tg-C321R mutants treated for 4 wk when administered at 3 wk of age. The pretreatment albuminuria was measured at P17–P19 (n = 6 per group for vehicle or K201-injected Tg-C321R mice and n = 8 per group for vehicle or K201-injected Lamb2+/− mice). Mean ± SD. **P < 0.01 by ANOVA. (C) Serum BUN of the indicated groups following 4 wk of K201 or 20% HBC treatment (n = 6 per group for vehicle or K201-injected Tg-C321R mice and n = 8 per group for vehicle or K201-injected Lamb2+/− mice). Mean ± SD. *P < 0.05. NS, not significant by ANOVA.